nach oben

Journal of Thrombosis and Thrombolysis

Erschienen in:

23.10.2021 | COVID-19 Zur Zeit gratis

Cellular and molecular mechanisms in COVID-19 coagulopathy: role of inflammation and endotheliopathy

verfasst von: Rossella Cacciola, Elio Gentilini Cacciola, Veronica Vecchio, Emma Cacciola

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Coronavirus 2 (CoV-2) infection or coronavirus disease 2019 (COVID-19) is frequently associated with microvascular thrombosis.The microthrombosis in COVID-19 is the result of the interplay between inflammation and endotheliopathy. Elevated interleukin-6 (IL-6) characterizes COVID-19 inflammation resulting in endotheliopathy and coagulopathy marked by elevated D-dimer (DD). Aim of this study is to identify and to describe the coagulation changes in 100 moderate COVID-19 patients having lung involvement and to determine the association of coagulopathy with the severity and prognosis.

Methods

Inflammation, endothelial and coagulation molecules were measured in moderate and mild disease.

Results

IL-6 and tumor necrosis factor-α (TNF-α) and tissue factor (TF), von Willebrand factor (VWF), and tissue factor pathway inhibitor (TFPI) significantly increased in moderate disease as well as D-dimer, thrombin antithrombin complex (TAT), Fibrinogen (Fib), platelet factor-4 (PF4), β-thromboglobulin (β-TG), P-selectin, and platelet adhesion. Shortened clotting time (CT) and clot formation time (CFT), high maximum clot firmness (MCF) and low LY at 30 min were present in 100% of moderate COVID-19 patients compared with mild COVID-19 patients.

Conclusions

These findings demonstrate that moderate COVID-19 has a profound inflammation associated with severee ndotheliopathy and intense coagulation activation uncontrolled by TFPI.

Attention should be paid to coagulopathy in COVID-19. Closely monitoring of coagulation and application of appropriate anticoagulation may improve the prognosis of moderate COVID-19 and to prevent the progression to severe COVID-19 disease.

Liao D, Zhou F, Luo L et al (2020) Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study. Lancet Haematol 7:e671-678PubMedPubMedCentral

Layton DS, Chudhary A, Bean AGD (2017) Breaking the chain of zoonoses through biosecurity in livestock. Vaccine 35(44):5967–5973 (eliminare)PubMed

Middeldorp S, Coppens M, van Haaps TF et al (2020) Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost 18(8):1995–2002PubMedPubMedCentral

Cattaneo M, Bertinato EM, Birocchi S et al (2020) Pulmonary embolism or pulmonary thrombosis in COVID-19? Is the recommendation to use high-dose heparin for thromboprophylaxis justified? Thromb Haemost 120:1230–1232PubMedPubMedCentral

Danzi GB, Loffi M, Galeazzi G et al (2020) Acute pulmonary embolism and COVID-19 pneumonia: a random association? Eur Heart J 41(19):1858PubMed

Rotzinger DC, Beigelman-Aubry C, von Garnier C et al (2020) Pulmonary embolism in patients with COVID-19: time to change the paradigm of computed tomography. Thromb Res 190:58–59PubMedPubMedCentral

Fox SE, Akmatbekov A, Harbert JL et al (2020) Pulmonary and cardiac pathology in African American patients with COVID-10: an autopsy series from New Orleans. Lancet Respir Med 8(7):681–686 (published online ahead of print 27 May 2020)PubMedPubMedCentral

Du Y, Tu L, Zhu P et al (2020) Clinical features of 85 fatal cases of COVID-19 from Wuhan: a retrospective observational study. Am J Respir Crit Care Med 201(11):1372–1379PubMedPubMedCentral

Middleton EA, HE X-Y, Denorme F et al (2020) Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood 136(10):1169–1179PubMed

10.

Hottz ED, Azevedo-Quintanilha IG, Palhinha L et al (2020) Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVOD-19. Blood 136(11):1330–1341PubMed

11.

Tang N, Li D, Wang X et al (2020) Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 18(4):844–847PubMedPubMedCentral

12.

Giamarellos-Bourboulis EJ, Netea MG, Rovina N et al (2020) Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe 27(6):992-1000. e3PubMedPubMedCentral

13.

Zhou F, Yu T, Du R et al (2020) Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a restrospective cohort study. Lancet 395(10229):1054–1062PubMedPubMedCentral

14.

Connors JM, Levy JH (2020) COVID-19 and its implications for thrombosis and anticaogulation. Blood 135(23):2033–2040PubMed

15.

Engelmann B, Massberg S (2013) Thrombosi as an intravascular effector of innate immunity. Nat Rev Immnunol 13(1):34–45

16.

Delabranche X, Helms J, Meziani F (2017) Immunohaemostasis: a new view on haemostasis during sepsis. Ann Intensive Care 7(1):117PubMedPubMedCentral

17.

Jackson SP, Darbousset R, Schoenwaelder SM (2019) Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms. Blood 133(9):906–918PubMed

18.

Woei-A-Jin FJ, van der Starre WE, Tesselaar ME et al (2014) Procoagulant tissue factor activity on microparticles is associated with disease severity and bacteremia in febrile urinary tract infections. Thromb Res 133(5):799–803PubMed

19.

Gould TJ, Lysov Z, Swystun LL et al (2016) Canadian critical care translational biology group extracellular histones increase tissue factor activity and enhance thrombi generation by human blood monocytes. Shock 46(6):655–662PubMed

20.

Iba T, Levy JH (2018) Inflammation and thrombosis: roles of neutrophils, platelets, and endothelial cells and their interactions in thrombus formation during sepsis. J Thromb Haemost 16(2):231–241PubMed

21.

Peter L, Giesen A, Rauch U et al (1999) Blood-borne tissue factor: Another view of thrombosis. Proc Natl Acad Sci USA 96:2311–2315

22.

Esmon CT (2003) Inflammation and thrombosis. J Thromb Haemost 1:1343–1348PubMed

23.

Bar-Shavit R, Kahn AJ, Mann KG et al (1986) Identifiaction of a thrombin sequence with growth factor activity in on macrophages. Proc Natl Acad Sci USA 83:976–980PubMedPubMedCentral

24.

Lorant DE, Patel KD, McIntyre TM et al (1991) Coexpression of GMP-140 and PAF by endothelium stimulated by histamine or thrombin: a juxtacrine system for adhesion and activation of neutrophils. J Cell Biol 115:223–234PubMed

25.

Pendurthi UR, Alok D, Rao LVM (1997) Binding of factor VIIa to tissue factor induces altetations in gene expression in human fibroblast cells: upregulation of poly (A) polymerase. Proc Natl Acad Sci USA 94:2598–2603

26.

Miller DL, Yaron R, Yellin MJ (1998) CD40L-CD40 interactions regulate endothelial cell surface tissue factor and thrombomodulin expression. J Leukoc Biol 63:373–379PubMed

27.

Andrè P, Srinivasa Prasad KS, Denis CV et al (2002) CD40L stabilizes arterial thrombi by a β3 integrin-dependent mechanism. Nat Med 8:247–252PubMed

28.

Henn V, Slupsky JR, Grafe M et al (1998) CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391:591–594PubMed

29.

Burstein SA (1997) Cytokines, platelet productions and hemostasis. Platelets 8:93–104PubMed

30.

Taylor FB, Chang A, Esmon CT et al (1987) Protein C prevents the coagulopathic and lethal effects of E. coli infusion in the baboon. J Clin Investig 79:918–925PubMedPubMedCentral

31.

Lupu C, Lupu F, Dennechy U et al (1995) Thrombin induces the redistribution and acute release of tissue factor pathway inhibitor from specific granules within human endothelial cells in culture. Arterioscler Thromb Vasc Biol 15:2055–2062PubMed

32.

Goldfarb RD, Glock D, Johnson K et al (1998) Randomized, blinded, placebo-controlled trial of tissue factor pathway inhibitor in porcine septic shock. Shock 10(4):258–264PubMed

33.

Matyal R, Vin Y, Delude RL et al (2001) Extremely low doses of tissue factor pathway inhibitor decrease mortality in a rabbit model of septic shock. Intensive Care Med 27(8):1274–1280PubMed

34.

Creasey AA, Chang AC, Feigen L et al (1993) Tissue factor pathway inhibitor reduces mortality from Escherichia Coli septic shock. J Clin Investig 91(6):2850–2860PubMedPubMedCentral

35.

de Jonge E, Dekkers PE, Creasey AA et al (2000) Tissue factor pathaway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood 95(4):1124–1129PubMed

36.

Abraham E, Reinhart K, Svoboda P et al (2001) Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, rabdomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med 29(11):2081–2089PubMed

37.

Huang C, Wang Y, Li X et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China Lancet 395(10223):497–506PubMed

38.

Iba T, Levy JH, Warkentin TE, Thachil J et al (2019) Scientific and standardization committee on DIC, and the scientific and standardization committee on perioperative and clinical care of the international society of thrombosis and haemostasis. Diagnosis and management of sepsi-induced coagulopathy and disseminated intravascular coagulation. J Thromb Haemost 17(11):1989–1994PubMed

39.

Taylor FB, Toh CH, Hoots WK et al (2001) Subcommittee on disseminated intravascular coagulation (DIC) of the international society on thrombosis and haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 86(5):1327–1330PubMed

40.

Iba T, Levy JH, Yamakawa K et al (2019) Scientific and standadization committee on DIC of the international society on thrombosis and haemostasis. Proposal of a two-step process for the diagnosis of sepsis-induced disseminated intravascular coagulation. J Thromb Haemost 17(8):1265–1268PubMed

41.

Tang N, Bai H, Chen X et al (2020) Anticoagulant treatmemt is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 18(5):1094–1099PubMed

42.

Siegal DM, Barnes GD, Langlois NL et al (2020) A toolkit for the collection of thrombosis-related data elements in COVID-19 clinical studies. Blood Adv 4(24):6259–6273PubMedPubMedCentral

43.

Suzuki K, Wada H, Imai H et al (2018) Subcommittee on disseminated intravascular coagulation. A re-evaluation of the D-dimer cut-off value for making a diagnosis according to the ISTH overt-DIC diagnostic criteria: communication from the SSC of the ISTH. J Thromb Haemost 16(7):1442–1444PubMed

44.

Schnittler HJ, Feldmann H (2003) Viral hemorrhagic fever-a vascular disease? Thromb Haemost 89(6):967–972PubMed

45.

Rittirsch D, Flierl MA, Ward PA (2008) Harmful molecular mechanisms in sepsis. Nat Rev Immunol 8(10):776–787PubMedPubMedCentral

46.

Iba T, Levy JH (2019) Derangement of the endothelial glycolalyx in sepsis. J Thromb Haemost 17(2):283–294PubMed

47.

Varga Z, Flammer AJ, Steiger P et al (2020) Endothelial cell infection and endothelitis in COVID-19. Lancet. https://doi.org/10.1016/S0140-6736(20)30937-5 (published online ahead of print 20 April 2020)CrossRefPubMedPubMedCentral

48.

Iba T, Levy JH, Thachil J et al (2019) Scientific and standardization committee on DIC of the international society on thrombosis and haemosatsis. The progression from coagulopathy to disseminated intravsacular coagulation in representative undelying diseases. Thromb Res 179:11–4. (n. 51)PubMed

49.

Iba T, Levy JH, Wada H et al (2019) Subcommittee on disseminated intravascular coagulation. Differential diagnoses for sepsis-induced disseminated intravascular coagulation: communication from the SSC of the ISTH. J Thromb Haemost 17(2):415–419PubMed

50.

Ranucci M, Ballotta A, Di Dedda U et al (2020) The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost. https://doi.org/10.1111/jth.14854CrossRefPubMedPubMedCentral

51.

National Health Commission, National Administration of Traditional Chinese Medicine (2020) Diagnosis and treatment protocol for novel coronavirus pneumonia (trial version 7). Chin Med J 133:1087–1095

52.

Fox SE, Akmatbekov A, Harbert JL et al (2020) Pulmonary and cardiac pathology in COVID-19: the first autpsy series from New Orleans. MedRxiv 22:1–358

53.

Lax SF, Skok K, Zechner P et al (2020) Pulmonary arterial thrombosis in COVID-19 with fatal outcome: results from a prospective, single-center, clinicopathologic case series. Ann Intern Med 14:M20-2566

54.

Zhang T, Sun LX, Feng RE (2020) Comparison of clinical and pathological features between severe acute respiratory syndrome and coronavirus disease 2019. Zhonghua Jie He He Hu Xi Za Zhi 43(6):496–502 (Chinese)PubMed

55.

Mucha SR, Dugar S, McCrae K et al (2021) Update to coagulopathy in COVID-19: manifestations and management. Clevel Clin J Med. https://doi.org/10.3949/ccjm.87a.ccc024-upCrossRef

56.

Cui S, Chen S, Li X et al (2020) Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost 18(6):1421–1424PubMed

57.

Klok FA, Kruip MJ, van der Meer NJ et al (2020) Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 191:145–147PubMedPubMedCentral

58.

Levi M, Scully M (2018) How I treat disseminated intravscular coagulation. Blood 131(8):845–854PubMed

59.

Liu Y, Gao W, Guo W et al (2020) Prominent coagulation disorder is closely related to inflammatory response and could be as a prognostic indicator for ICU patients with COVID-19. J Thromb Thrombolysis 50(4):825–832PubMedPubMedCentral

60.

Helms J, Tacquard D, Severac F et al (2020) High risk of thrombosis in patients in severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med 46(6):1089–1098PubMedPubMedCentral

61.

Chaudhary R, Kreutz RP, Bliden KP et al (2020) Personalizing antithrombotic therapy in COVID-19: role of thromboelastography and thromboelastometry. Thromb Haemost 120:1594–1596PubMed

62.

Jose RJ, Manuel A (2020) COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med 8(6):e46–e47PubMed

63.

Schechter ME, Andrade BB, He T et al (2017) Inflammatory monocytes expressing tissue factor drive SIV and HIV coagulopathy. Sci Transl Med 9(405):5441

64.

Manne BK, Denorme F, Middleton EA et al (2020) Platelet gene expression and function in patients with COVID-19. Blood 136(11):1317–1329PubMed

65.

Maatman TK, Jalali F, Feizpour C et al (2019) Routine venous thromboembolism prophylaxis may be inadequate in the hypercoagulable state of severe coronavirus disease. Crit Care Med. https://doi.org/10.1097/CCM.0000000000004466CrossRef

66.

Wright FL, Vogler TO, Moore EE et al (2020) Fibrinolysis shutdown correlation with thromboembolic events in severe COVID-19 infection. J Am Coll Surg 231(2):193–203PubMedPubMedCentral

Titel: Cellular and molecular mechanisms in COVID-19 coagulopathy: role of inflammation and endotheliopathy
verfasst von: Rossella Cacciola
Elio Gentilini Cacciola
Veronica Vecchio
Emma Cacciola
Publikationsdatum: 23.10.2021
Verlag: Springer US
Schlagwort: COVID-19
Erschienen in: Journal of Thrombosis and Thrombolysis / Ausgabe 2/2022
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-021-02583-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Introduction

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2022

Background of fatal pulmonary embolism: an analysis of all diagnosed fatal pulmonary embolism in 2015–2018 from Hospital District of Helsinki and Uusimaa

Patterns of vascular access device use and thrombosis outcomes in patients with COVID-19: a pilot multi-site study of Michigan hospitals

Clinical outcomes of surgical embolectomy versus catheter-directed thrombolysis for acute limb ischemia: a nationwide cohort study

Metformin use in patients hospitalized with COVID-19: lower inflammation, oxidative stress, and thrombotic risk markers and better clinical outcomes

Fibrinspecific liposomes as a potential method of delivery of the thrombolytic preparation streptokinase